Literature DB >> 11591102

Clinical management and treatment of vasculitis.

D Jayne1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11591102     DOI: 10.1007/s002810100080

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


× No keyword cloud information.
  111 in total

1.  Intravenous pulse versus oral administration of cyclophosphamide: comment on the article by Haubitz et al.

Authors:  C O Savage; D R Jayne
Journal:  Arthritis Rheum       Date:  1999-09

Review 2.  Pathogenesis of ANCA-associated systemic vasculitis.

Authors:  L Harper; C O Savage
Journal:  J Pathol       Date:  2000-02       Impact factor: 7.996

Review 3.  Classification and epidemiology of the vasculitides.

Authors:  R A Watts; D G Scott
Journal:  Baillieres Clin Rheumatol       Date:  1997-05

4.  Endocarditis associated with ANCA.

Authors:  A Soto; C Jorgensen; F Oksman; L H Noel; J Sany
Journal:  Clin Exp Rheumatol       Date:  1994 Mar-Apr       Impact factor: 4.473

5.  Reduced gonadal toxicity after i.v. cyclophosphamide administration in patients with nonmalignant diseases.

Authors:  M Haubitz; C Ehlerding; K Kamino; K M Koch; R Brunkhorst
Journal:  Clin Nephrol       Date:  1998-01       Impact factor: 0.975

6.  Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups.

Authors:  P Halloran; T Mathew; S Tomlanovich; C Groth; L Hooftman; C Barker
Journal:  Transplantation       Date:  1997-01-15       Impact factor: 4.939

7.  ANCA and predicting relapse in systemic vasculitis.

Authors:  D R Jayne; G Gaskin; C D Pusey; C M Lockwood
Journal:  QJM       Date:  1995-02

8.  Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study.

Authors:  M Haubitz; S Schellong; U Göbel; H J Schurek; D Schaumann; K M Koch; R Brunkhorst
Journal:  Arthritis Rheum       Date:  1998-10

9.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group.

Authors:  C A Stegeman; J W Tervaert; P E de Jong; C G Kallenberg
Journal:  N Engl J Med       Date:  1996-07-04       Impact factor: 91.245

10.  Influence of immunoadsorption on the removal of immunoglobulin G autoantibodies in crescentic glomerulonephritis.

Authors:  V L Esnault; A Testa; D R Jayne; J P Soulillou; J Guenel
Journal:  Nephron       Date:  1993       Impact factor: 2.847

View more
  1 in total

Review 1.  [Rapidly progressive glomerulonephritis:classification, pathogenesis and clinical management].

Authors:  R Birck; F J Van Der Woude
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.